MangoceuticalsMGRX +1.76%26 Gross Margin % is 42.65% as of Mar. 2026, which is 26% below its 10-year median of 57.33. GuruFocus rates MGRX with a GF Score™ of 26/100 and a GF Value™ of $0.31 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 629 Healthcare Providers & Services companies, Mangoceuticals ranks better than 63.12% on this metric.
The historical rank and industry rank for Mangoceuticals's Gross Margin % or its related term are showing as below:
MGRX'
s Gross Margin % Range Over the Past 10 Years
Min: 52.42 Med: 57.33 Max: 61.69
Current: 52.42
During the past 5 years, the highestGross Margin % of Mangoceuticals was 61.69%. The lowest was 52.42%. And the median was 57.33%.
MGRX's Gross Margin % is ranked better than 63.12% of 629
companies
in the Healthcare Providers & Services industry
Industry Median: 40.09
vs MGRX: 52.42
Mangoceuticals had a gross margin of 42.65% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Mangoceuticals was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Mangoceuticals had a gross margin of 42.65% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Mangoceuticals Gross Margin % Related Terms
Mangoceuticals Gross Margin % Historical Data
* Premium members only.
The historical data trend for Mangoceuticals's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MGRX vs WLSS, ACON, VSEE: Gross Margin % Comparison
For the Health Information Services subindustry, Mangoceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangoceuticals Gross Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Mangoceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Mangoceuticals (MGRX) has a Gross Margin % of 42.65% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Mangoceuticals and its competitors. This is 26% below median its historical median of 57.33. Over the past decade, Mangoceuticals' Gross Margin % has ranged from 52.42 to 61.69. According to the industry distribution chart, Mangoceuticals ranks #232 out of 629 companies in the Healthcare Providers & Services industry, placing it in the top 36.9%.
Is Mangoceuticals' Gross Margin % too high?
Mangoceuticals' current Gross Margin % of 42.65% is 26% below median its 10-year median of 57.33. Over the past 10 years, this metric has ranged from a low of 52.42 to a high of 61.69. The Healthcare Providers & Services industry median Gross Margin % is 40.09. Mangoceuticals' value of 42.65% is 6.4% above this industry median. Based on the distribution chart, Mangoceuticals ranks #232 out of 629 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Mangoceuticals has a GF Score™ of 26/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mangoceuticals' Gross Margin % compare to WLSS and ACON?
According to the Healthcare Providers & Services industry distribution chart, Mangoceuticals ranks #232 out of 629 companies for Gross Margin %. This puts Mangoceuticals in the upper half of its industry. The industry median Gross Margin % is 40.09. Mangoceuticals' value of 42.65% is 6.4% above this benchmark. Historically, Mangoceuticals' own Gross Margin % has ranged from 52.42 to 61.69 over the past decade. While the company's 10-year median is 57.33 vs. the industry median of 40.09, Mangoceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Healthcare Providers & Services company?
The median Gross Margin % among Healthcare Providers & Services companies is 40.09, based on 629 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mangoceuticals's current Gross Margin % of 42.65% is 6.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Mangoceuticals and its competitors. For the Healthcare Providers & Services industry, the median Gross Margin % is 40.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangoceuticals's current Gross Margin % is 42.65%, which is 26% below median its own 10-year median of 57.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangoceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mangoceuticals (MGRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.31, compared to a current price of $0.36 — trading 17.6% above its estimated fair value. The current Gross Margin % is 42.65%, which is 26% below median its 10-year median of 57.33 and 6.4% above the Healthcare Providers & Services industry median of 40.09. Mangoceuticals' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Mangoceuticals (MGRX), the current Gross Margin % is 42.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangoceuticals (MGRX) Overvalued in 2026?
Based on GuruFocus' analysis, Mangoceuticals stock appears to be overvalued.
The current stock price of $0.36 is trading 17.6% above its estimated GF Value™ of $0.31.
GuruFocus considers Mangoceuticals to be Modestly Overvalued.
Key valuation signals for MGRX:
Gross Margin %: 42.65% (26% below median its 10-year median of 57.33)
GF Value™: $0.31 vs. price of $0.36 (17.6% above fair value)
Industry Position: 6.4% above the Healthcare Providers & Services median (#232 of 629)
No single metric tells the full story. See the MGRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
26GF Score
Get the complete analysis for MGRX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGRX has been successfully added to your 
